STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT02943590
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Registry
-
NCT02943590
-
- Other papers using this trial's data
- Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial
- Atorvastatin and left atrial function during anthracycline-based chemotherapy
- Atorvastatin and left ventricular strain during anthracycline-based chemotherapy
- Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
- Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02943590. Randomized; double masking; primary purpose treatment. Start 2017-01-13 (actual); primary completion 2022-09-16 (actual). Results posted on 2023-12-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
- Condition
- Heart Failure
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Atorvastatin
- Lead sponsor
- Massachusetts General Hospital
- Collaborator
- Dana-Farber Cancer Institute
- Collaborator
- Brigham and Women's Hospital
Record details
- Record id
cardio:ct-nct02943590- Content hash
592807cd6c27bc7ee7b472a5c18b3056eec730ce0b9f7c1a36e16adbc3cecdd0